Raseglurant

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Raseglurant
Raseglurant.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H13FN2
Molar mass240.276 g/mol g·mol−1
3D model (JSmol)

Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety.[1][2][3] It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.[3][4][5]

See also[edit]

References[edit]

  1. ^ Annual Reports in Medicinal Chemistry. Academic Press. 31 December 2012. pp. 80–. ISBN 978-0-12-397214-9.
  2. ^ "Don't Dodge the Dentist – Tips for Dealing with Dental Anxiety". Retrieved 2017-04-05.
  3. ^ a b Murray B. Stein; Thomas Steckler (30 July 2010). Behavioral Neurobiology of Anxiety and Its Treatment. Springer Science & Business Media. pp. 397–. ISBN 978-3-642-02912-7.
  4. ^ Celia Dominguez (18 November 2010). Neurodegenerative Diseases. Springer Science & Business Media. pp. 120–. ISBN 978-3-642-16758-4.
  5. ^ Nicholas J. Shaheen (25 March 2013). Benign and Neoplastic Conditions of the Esophagus, An Issue of Gastroenterology Clinics,. Elsevier Health Sciences. pp. 119–. ISBN 1-4557-7175-9.

External links[edit]